This panel will explore how partnership structures are evolving across the biotech lifecycle. Using recent European examples, including VarmX and Memo Therapeutics, the discussion will examine how deal design is adapted to asset maturity, available data and execution requirements. Spanning early platform collaborations through to late-stage development agreements, the panel brings together biotech, investor and industry perspectives, and will also reflect on Europe’s role in supporting cross-border collaboration and company building.
Tuesday, May 5, 13:00 - 13:45, room Kairo
| Name | Position | Institution |
|---|---|---|
| Rémi Droller | Managing Partner | Kurma Partners |
| Name | Position | Institution |
|---|---|---|
| Hervé Gisserot | Executive Vice President | CSL |
| Emmanuelle Lecomte-Brisset | Senior Vice President | CSL |
| Martijn Negen | Chief Operating Officer | VarmX |
| Lars Spenger | Chief Financial Officer | Memo Therapeutics |
CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL -including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor - provides lifesaving products to patients in more than 100 countries and employs 29,000 people.
